Skip to Content
  • Patients & Caregivers
  • Health Care Professionals
  • Text: Increase text size Decrease text size
  • Print
 
Patient Stories.

You must have Javascript enabled and Flash 8.0 or above to view the Patient Stories.
Please download Flash here

Cystic Fibrosis Community — 13-17 Years Old

Topics for Teens

Being a teenager has its own unique obstacles to face. We know this, but at least many teenagers have had to face many of the same issues over the years. Explore some the links below that are of particular interest to you.

Indication and Usage

Daily administration of Pulmozyme in conjunction with standard therapies is indicated in the management of cystic fibrosis (CF) patients to improve pulmonary function. In patients with an FVC ≥40% of predicted, daily administration of Pulmozyme has also been shown to reduce the risk of respiratory tract infections requiring parenteral antibiotics.

Safety and efficacy of daily administration have not been demonstrated in patients for longer than 12 months.

Important Safety Information

Pulmozyme should not be used in patients who are allergic to any of its ingredients. Pulmozyme should be used in conjunction with standard therapies for CF. When starting Pulmozyme therapy, patients may experience change in or loss of voice, discomfort in the throat, chest pain, red watery eyes, rash, dizziness, fever, or runny nose. These side effects are usually mild and short-lived.

Pediatric Use

There is a limited amount of information available concerning the usage of Pulmozyme in patients who are younger than 5 years. The decision to use Pulmozyme in these patients is made after considering the potential for a benefit in lung function or in decreasing the risk of RTEs.

Important Safety Considerations

The safety of Pulmozyme given by daily inhalation for 2 weeks has been studied using 98 CF patients with 65 of them aged 3 months to <5 years (younger group) and 33 aged 5 years to ≤10 years (older group). The PARI BABY™ reusable nebulizer (which uses a face mask instead of a mouthpiece) was used in patients who were unable to show that they could breathe in or out using their mouth throughout the entire treatment period. There were more reports of cough, moderate to severe cough, runny nose, and rash in the younger group of patients. Other reported events tended to be of mild to moderate severity. The kind of side effects reported was similar to that of Pulmozyme when used in the larger trials that studied older patients.

For further information, please see the Pulmozyme full prescribing information. If you have questions, please discuss them with your CF healthcare team.

Join the Community

Registering with our Cystic Fibrosis Community is fast and easy. Simply fill out the required information and then confirm your submission by entering in the two security words that appear in the text box. Soon you'll be part of our community!

Share My Story

Share this page

close

Email this page